NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis $0.30 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock About Telesis Bio Stock (NASDAQ:TBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Telesis Bio alerts:Sign Up Key Stats Today's Range$0.30▼$0.3050-Day Range$0.01▼$0.9052-Week Range$0.01▼$6.17VolumeN/AAverage Volume6,759 shsMarket Capitalization$540.60 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California. Read More Telesis Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreTBIO MarketRank™: Telesis Bio scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Telesis Bio. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Telesis Bio is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telesis Bio is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTelesis Bio has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Telesis Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.18% of the float of Telesis Bio has been sold short.Short Interest Ratio / Days to CoverTelesis Bio has a short interest ratio ("days to cover") of 25, which indicates bearish sentiment.Change versus previous monthShort interest in Telesis Bio has recently decreased by 13.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelesis Bio does not currently pay a dividend.Dividend GrowthTelesis Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.18% of the float of Telesis Bio has been sold short.Short Interest Ratio / Days to CoverTelesis Bio has a short interest ratio ("days to cover") of 25, which indicates bearish sentiment.Change versus previous monthShort interest in Telesis Bio has recently decreased by 13.79%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Telesis Bio this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telesis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders24.50% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.63% of the stock of Telesis Bio is held by institutions.Read more about Telesis Bio's insider trading history. Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TBIO Stock News HeadlinesTelesis Bio Inc (TBIO) Stock Forums - Investing.comJune 29, 2025 | investing.comTelesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene SynthesisMay 28, 2025 | finance.yahoo.comHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing to invest in new "E.I." Tech, which one expert estimates will grow by 200,000%. Becoming bigger than the automobile, PC, and cell phone markets... COMBINED!July 4 at 2:00 AM | Behind the Markets (Ad)Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisMarch 20, 2025 | finance.yahoo.comTelesis Bio Announces Departure of Chief Legal OfficerOctober 25, 2024 | markets.businessinsider.comTelesis Bio Shares Double After News of Beckman Coulter Life Sciences CollaborationSeptember 27, 2024 | marketwatch.comWhat's Going On With Telesis Bio Shares Thursday?September 27, 2024 | msn.comTelesis Bio Stock Is Soaring Wednesday: What's Going On?September 26, 2024 | msn.comSee More Headlines TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed this year? Telesis Bio's stock was trading at $0.40 at the start of the year. Since then, TBIO stock has decreased by 25.0% and is now trading at $0.30. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) announced its earnings results on Monday, November, 8th. The company reported ($6.12) earnings per share for the quarter, missing analysts' consensus estimates of ($5.04) by $1.08. The company earned $2.79 million during the quarter, compared to analyst estimates of $2.93 million. When did Telesis Bio's stock split? Shares of Telesis Bio reverse split on Thursday, May 9th 2024.The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), Pfizer (PFE), PayPal (PYPL), SoFi Technologies (SOFI), Plug Power (PLUG) and XPeng (XPEV). Company Calendar Last Earnings11/08/2021Today7/04/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees200Year FoundedN/AProfitability EPS (Trailing Twelve Months)($28.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.72 million Net Margins-336.59% Pretax Margin-334.81% Return on EquityN/A Return on Assets-61.89% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.06 Sales & Book Value Annual Sales$225.09 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book2.14Miscellaneous Outstanding Shares1,802,000Free Float1,360,000Market Cap$540.60 thousand OptionableOptionable Beta0.96 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:TBIO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.